Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464655 | 0.82 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1CYP3A4 | |
| SCHEMBL15621595 | 0.81 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL445761 | 0.79 | HSP90AA1 (0.59) | HSP90AA1HSP90AB1 | |
| SCHEMBL2476428 | 0.78 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL448878 | 0.78 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL448959 | 0.78 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1 | |
| SCHEMBL451123 | 0.77 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1 | |
| SCHEMBL446586 | 0.76 | KMT2A (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL446362 | 0.76 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1 | |
| SCHEMBL445921 | 0.76 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2370402-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corp. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065512-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | PKD1, PKD2, PCNA | HSP90AA1 2300/4885HSP90AB1 1711/4885TRPA1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.